Understanding the molecular mechanisms of colorectal cancer (CRC) is crucial for advancing treatment strategies. Using g.nome®, our end-to-end #omics analysis platform, we conducted a comprehensive single-cell transcriptomics analysis with publicly accessible RNA-seq datasets, efficiently replicating the identification of key biomarkers. This analysis provides essential insights into CRC progression and the development of personalized treatments. g.nome® simplifies complex genomic analysis, reducing technical barriers and enabling researchers to derive meaningful insights quickly. By integrating powerful scRNA-seq tools like Seurat into a user-friendly interface, g.nome ensures robust data processing and analysis. Dive deeper into our study and explore how these tools facilitated our research: https://lnkd.in/g3dcWmF7 #omics #precisionmedicine #cancerresearch
Almaden Genomics’ Post
More Relevant Posts
-
Head Translational Medicine & Diagnostics at Nucleai. Associate Editor of the journal Artificial Intelligence in Precision Oncology. I am a Dad, an Ironman, and support the Kyle Pease foundation.
Multiplex Immunofluorescence (mIF) allows the analysis of protein expression simultaneously for multiple markers with a single FFPE section. Join this seminar to learn how to apply mIF for exploratory biomarker discovery, and how powerful this platform is to learn biological insights. Ettai, Arutha, and their teams found metabolic regulation as a critical pathway in IO response.
Join us next Thursday for a Genetic Engineering & Biotechnology News webinar where Ettai Markovits, Director of Biomedical Research, and Arutha Kulasinghe from The University of Queensland will discuss how AI-based spatial analysis of mIF data can accelerate the discovery of clinically relevant biomarkers that can predict response and resistance mechanisms to immunotherapy. Discover how spatial biomarkers can advance next-gen cancer treatments. 📅 Date: Thursday, May 2, 2024 ⏰ Time: 8:00 AM PDT | 11:00 AM EDT | 17:00 CEST Secure your spot now! RSVP here ➡ https://hubs.li/Q02t_x9r0 #spatialbiomarkers #spatialbiology #immunotherapy #biomarkers #digitalpathology #biomarkers #mIF, #multiplex #Immunofluorescence
-
-
Cancer Profiling Market worth $16.0 billion 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/g5Tt2iAg The global #cancer #profiling market in terms of revenue was estimated to be worth $9.7 billion in 2022 and is poised to reach $16.0 billion by 2027, growing at a CAGR of 10.6% from 2022 to 2027. Illumina. QIAGEN NeoGenomics Laboratories Sysmex Corporation HTG Molecular Diagnostics Predictive Oncology (Helomics) Caris Life Sciences NanoString Technologies, Inc. Guardant Health Foundation Medicine F. Hoffmann-La Roche Ltd Thermo Fisher Scientific GenScript Tempus AI Hologic, Inc. Exact Sciences Labcorp Personalis, Inc. Boreal Genomics Strand Life Sciences Lucence ACT Genomics (行動基因) IMBdx Perthera AI Agendia
-
-
Our genomics experts will be attending the Vizgen & Labroots webinar on July 25th to dive deeper into Spatial Transcriptomics. We'll explore: • Interactions between cell types like cancer, immune cells, fibroblasts, and endothelial cells. • How Spatial Transcriptomics maps gene expression within tissue sections for a detailed view of gene activity. • Insights into tumor evolution, immune evasion, and therapeutic resistance. Stay tuned for key takeaways and how our experts can leverage these insights to drive your research forward!
🌟Join the Vizgen & Labroots #Webinar! 🗓️ Date: Thursday, July 25, 2024 🕒 Time: 2:00 PM SGT | 8:00 AM CEST Topic: How can clinicians use spatial transcriptomics data to interpret the complexity of tumor microenvironment? 🎙️ Speaker: Dr. Kwon Joong Na, Chief Medical Officer, Portrai Inc. Discover how #SpatialTranscriptomics provides a high-resolution view of gene activity across the TME, helping clinicians study tumor heterogeneity, trace cancer cell lineage, and identify biomarkers essential for developing effective immunotherapies. 🔗 Register here: https://hubs.ly/Q02Gw77V0 #SpatialTranscriptomics #CancerResearch #TumorMicroenvironment #Webinar #Vizgen #Portrai
-
-
Interested to know how spatial transcriptomics can uncover the tumor microenvironment, leading to biomarker discovery for developing effective immunotherapies? Check out Vizgen's webinar on 25 July!
🌟Join the Vizgen & Labroots #Webinar! 🗓️ Date: Thursday, July 25, 2024 🕒 Time: 2:00 PM SGT | 8:00 AM CEST Topic: How can clinicians use spatial transcriptomics data to interpret the complexity of tumor microenvironment? 🎙️ Speaker: Dr. Kwon Joong Na, Chief Medical Officer, Portrai Inc. Discover how #SpatialTranscriptomics provides a high-resolution view of gene activity across the TME, helping clinicians study tumor heterogeneity, trace cancer cell lineage, and identify biomarkers essential for developing effective immunotherapies. 🔗 Register here: https://hubs.ly/Q02DQW3K0 #SpatialTranscriptomics #CancerResearch #TumorMicroenvironment #Webinar #Vizgen #Portrai
-
-
The success of your research depends on the methodic and accurate selection of the most relevant tumor models. Lumin, Champions' integrated software solution, eliminates the guesswork and gives you access to the most comprehensive model characterization data in the industry. Explore Champions’ patient-derived preclinical model characteristics: ☑️Clinical annotations ☑️Proprietary genomic and proteomic profiles ☑️Proprietary in vivo pharmacological profiles Make data-driven decisions with confidence and accelerate your oncology research programs. Explore here: https://hubs.li/Q02y21pL0 #Lumin #modelselection #omics #genomics #proteomics #oncologyresearch #cancerresearch #clinicalannotations #oncology
-
-
Cancer Profiling Market worth $16.0 billion by 2027 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dvdEwezB The global #cancer #profiling market in terms of revenue was estimated to be worth $9.7 billion in 2022 and is poised to reach $16.0 billion by 2027, growing at a CAGR of 10.6% from 2022 to 2027. #biotechnologyindustry Illumina. QIAGEN NeoGenomics Laboratories Sysmex Corporation HTG Molecular Diagnostics Predictive Oncology (Helomics) Caris Life Sciences NanoString Technologies, Inc. Guardant Health Foundation Medicine F. Hoffmann-La Roche Ltd Thermo Fisher Scientific GenScript Tempus AI Hologic, Inc. Exact Sciences Labcorp Personalis, Inc. Boreal Genomics Strand Life Sciences Lucence ACT Genomics (行動基因) IMBdx Perthera AI Agendia
-
-
Dive into this Bio-Techne case study and see the impact of their multiomics platform on colorectal cancer screening as the integration of genomics, transcriptomics, epigenomics, and proteomics opens new doors for enhanced classification. Stay tuned for insights into downstream assay development! Download the Application Note for an in-depth look! >>> https://bit.ly/3wigxIE
Visualize the future of precision medicine with bio-techne’s multiomics platform: CRC case study
biotechniques.com
-
We are presenting new data at #ESMO24. This study compared the gap between panTRK IHC testing and NGS fusion confirmation for NTRK or additional actionable fusions, as patients in certain community settings may only be tested for NTRK fusions following a positive IHC screen result. Bookmark these details to view the poster during #ESMO • Poster title: Real World Analysis of Actionable Gene Fusions Identified by NGS and Correlation with IHC in 422 Patients from the Community • Onsite poster display date: Sunday, September 15, 2024 • Session: Biomarkers and Translational research • Presentation Number: 78P • Speakers: Dr Hatim Husain (UCSD, La Jolla, United States of America) #NeoGenomics #NGS #NextGenerationSequencing #Oncology #NewData
-
-
🚨 Hump Day paper alert! 🐫 My article, "PD-1 Targeted Antibody Discovery Using AI Protein Diffusion" finally came out this morning in Technology in Cancer Research & Treatment. In this computational study, I used AI-based protein diffusion models to generate novel antibody candidates and then tested them `in silico`. Give it a read: https://lnkd.in/gGi-y4Gu GitHub repo: https://lnkd.in/guVU3shr #ai #drugdiscovery #llm #pharma #oncology #aiinmedicine #precisionmedicine #bioinformatics #computationalbiology #cloud #datascience #genomics #genetics #cancer #antibody 🐖
-
𝐂𝐚𝐧𝐜𝐞𝐫 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 by Type (Protein, Genetic), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnostics, R&D, Prognostics), Region - Global Forecast to 2026 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐅𝐑𝐄𝐄 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐧𝐝 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐓𝐎𝐂 𝐚𝐭 https://lnkd.in/dZiDJVWn The global 𝐂𝐚𝐧𝐜𝐞𝐫 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 in terms of revenue was estimated to be worth $12.4 billion in 2021 and is poised to reach $28.2 billion by 2026, growing at a CAGR of 17.7% from 2022 to 2027. 𝐌𝐚𝐣𝐨𝐫 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞: - F. Hoffmann-La Roche Ltd.( (Switzerland) - Thermo Fisher Scientific Inc. (US) - QIAGEN N.V. (Netherlands) - Bio-Rad Laboratories (US) - Illumina (US) #Cancerbiomarkersmarket #CancerBiomarkers
-
